Bruce W. Konicek

3.4k total citations
37 papers, 2.3k citations indexed

About

Bruce W. Konicek is a scholar working on Molecular Biology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Bruce W. Konicek has authored 37 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 12 papers in Immunology and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Bruce W. Konicek's work include PI3K/AKT/mTOR signaling in cancer (11 papers), Psoriasis: Treatment and Pathogenesis (9 papers) and Cancer Mechanisms and Therapy (5 papers). Bruce W. Konicek is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (11 papers), Psoriasis: Treatment and Pathogenesis (9 papers) and Cancer Mechanisms and Therapy (5 papers). Bruce W. Konicek collaborates with scholars based in United States, Canada and Austria. Bruce W. Konicek's co-authors include Jeremy R. Graff, Julia H. Carter, Blake Lee Neubauer, Ann M. McNulty, Eric G. Marcusson, George E. Sandusky, Bruce M. Colligan, Bernadette M. Hurst, James A. Deddens and Philip W. Iversen and has published in prestigious journals such as Journal of Biological Chemistry, Blood and PLoS ONE.

In The Last Decade

Bruce W. Konicek

36 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bruce W. Konicek United States	20	1.8k	447	344	325	240	37	2.3k
Thomas Hattier United States	6	2.1k 1.2×	488 1.1×	390 1.1×	227 0.7×	359 1.5×	7	2.6k
Nandini Dey United States	25	1.4k 0.8×	907 2.0×	432 1.3×	365 1.1×	183 0.8×	71	2.1k
Takaki Hiwasa Japan	25	1.3k 0.7×	474 1.1×	386 1.1×	168 0.5×	164 0.7×	132	2.1k
Qunsheng Ji China	25	1.5k 0.8×	686 1.5×	560 1.6×	538 1.7×	189 0.8×	50	2.5k
Stefan Hart Singapore	23	1.4k 0.8×	1.0k 2.3×	263 0.8×	273 0.8×	215 0.9×	30	2.7k
Juan Carlos Montero Spain	31	1.7k 0.9×	1.1k 2.5×	376 1.1×	233 0.7×	150 0.6×	90	2.8k
Janiel M. Shields United States	23	2.0k 1.1×	535 1.2×	348 1.0×	160 0.5×	140 0.6×	31	2.6k
Chirayu Goswami United States	25	1.1k 0.6×	443 1.0×	572 1.7×	235 0.7×	94 0.4×	44	1.8k
Landon J. Inge United States	21	1.1k 0.6×	433 1.0×	307 0.9×	242 0.7×	159 0.7×	41	1.7k
Levi J. Beverly United States	28	1.7k 0.9×	601 1.3×	403 1.2×	163 0.5×	303 1.3×	65	2.7k

Countries citing papers authored by Bruce W. Konicek

Since Specialization

Citations

This map shows the geographic impact of Bruce W. Konicek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruce W. Konicek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruce W. Konicek more than expected).

Fields of papers citing papers by Bruce W. Konicek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bruce W. Konicek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruce W. Konicek. The network helps show where Bruce W. Konicek may publish in the future.

Co-authorship network of co-authors of Bruce W. Konicek

This figure shows the co-authorship network connecting the top 25 collaborators of Bruce W. Konicek. A scholar is included among the top collaborators of Bruce W. Konicek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bruce W. Konicek. Bruce W. Konicek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

González‐Cantero, Álvaro, Burhan Engіn, S. Dogra, et al.. (2024). Comparative Effectiveness of Biologic Classes in Clinical Practice: Month 12 Outcomes from the International Observational Psoriasis Study of Health Outcomes (PSoHO). Advances in Therapy. 42(1). 233–245. 1 indexed citations

Armstrong, April W., Elisabeth Riedl, Patrick M. Brunner, et al.. (2024). Identifying Predictors of PASI100 Responses up to Month 12 in Patients with Moderate-to-severe Psoriasis Receiving Biologics in the Psoriasis Study of Health Outcomes (PSoHO). Acta Dermato Venereologica. 104. adv40556–adv40556. 2 indexed citations

Riedl, Elisabeth, Andreas Pinter, Antonio Costanzo, et al.. (2024). Baseline Characteristics and mNAPSI Change from Baseline Scores Through Month 12 for Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Nail Psoriasis Treated with Biologics from PSoHO. Dermatology and Therapy. 14(5). 1327–1335. 3 indexed citations

Gottlieb, Alice B., April W. Armstrong, Andrew Blauvelt, et al.. (2024). Benefits Over Five Years of Ixekizumab Treatment in Patients With Psoriasis Involving Challenging Body Areas. Journal of Drugs in Dermatology. 23(8). 619–625. 1 indexed citations

Gulliver, Wayne, Kyoungah See, Baojin Zhu, et al.. (2023). Development of Psoriasis Assessment Tools Among Patients in the CorEvitas Psoriasis Registry. PubMed. 8(2). 74–82.

Lockshin, Benjamin, Ryan W. Harrison, Robert R. McLean, et al.. (2022). Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry. Dermatology and Therapy. 12(12). 2797–2815. 6 indexed citations

Yan, S. Betty, Suzane L. Um, Victoria L. Peek, et al.. (2017). MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping. Investigational New Drugs. 36(4). 536–544. 33 indexed citations

Jacobson, Bruce A., Manish R. Patel, Bruce W. Konicek, et al.. (2015). Antisense oligonucleotide targeting eukaryotic translation initiation factor 4E reduces growth and enhances chemosensitivity of non-small-cell lung cancer cells. Cancer Gene Therapy. 22(8). 396–401. 27 indexed citations

Gkogkas, Christos G., Arkady Khoutorsky, Ruifeng Cao, et al.. (2014). Pharmacogenetic Inhibition of eIF4E-Dependent Mmp9 mRNA Translation Reverses Fragile X Syndrome-like Phenotypes. Cell Reports. 9(5). 1742–1755. 151 indexed citations

10.

Thobe, Megan N., Suzane L. Um, Victoria L. Peek, et al.. (2012). Abstract 2087: Detection of KRAS mutations in circulating tumor cells (CTCs) and in formalin-fixed, paraffin-embedded (FFPE) tissue using castPCR method. Cancer Research. 72(8_Supplement). 2087–2087. 1 indexed citations

11.

Konicek, Bruce W., Jennifer R. Stephens, Ann M. McNulty, et al.. (2011). Therapeutic Inhibition of MAP Kinase Interacting Kinase Blocks Eukaryotic Initiation Factor 4E Phosphorylation and Suppresses Outgrowth of Experimental Lung Metastases. Cancer Research. 71(5). 1849–1857. 159 indexed citations

12.

Parsons, Stephen H., Michele Dowless, Bruce W. Konicek, et al.. (2010). 148 Therapeutic targeting of the pro-survival transcription factor CREB sensitizes glioblastomas to temozolomide-based therapy. European Journal of Cancer Supplements. 8(7). 52–53. 1 indexed citations

13.

Graff, Jeremy R., Bruce W. Konicek, Rebecca L. Lynch, et al.. (2009). eIF4E Activation Is Commonly Elevated in Advanced Human Prostate Cancers and Significantly Related to Reduced Patient Survival. Cancer Research. 69(9). 3866–3873. 156 indexed citations

14.

Graff, Jeremy R., Bruce W. Konicek, Julia H. Carter, & Eric G. Marcusson. (2008). Targeting the Eukaryotic Translation Initiation Factor 4E for Cancer Therapy. Cancer Research. 68(3). 631–634. 264 indexed citations

15.

Konicek, Bruce W., Chad A. Dumstorf, & Jeremy R. Graff. (2008). Targeting the eIF4F translation initiation complex for cancer therapy. Cell Cycle. 7(16). 2466–2471. 40 indexed citations

16.

Graff, Jeremy R., James A. Deddens, Bruce W. Konicek, et al.. (2001). Integrin-linked kinase expression increases with prostate tumor grade.. PubMed. 7(7). 1987–91. 115 indexed citations

17.

Zinda, Michael, Mac Johnson, Candice L. Horn, et al.. (2001). AKT-1, -2, and -3 are expressed in both normal and tumor tissues of the lung, breast, prostate, and colon.. PubMed. 7(8). 2475–9. 132 indexed citations

18.

Graff, Jeremy R., Bruce W. Konicek, Ann M. McNulty, et al.. (2000). Increased AKT Activity Contributes to Prostate Cancer Progression by Dramatically Accelerating Prostate Tumor Growth and Diminishing p27Kip1 Expression. Journal of Biological Chemistry. 275(32). 24500–24505. 320 indexed citations

19.

Konicek, Bruce W., Xi Xia, T B Rajavashisth, & Melissa A. Harrington. (1998). Regulation of Mouse Colony-Stimulating Factor-1 Gene Promoter Activity by AP1 and Cellular Nucleic Acid-Binding Protein. DNA and Cell Biology. 17(9). 799–809. 34 indexed citations

20.

Harrington, Maureen A., et al.. (1997). Transcriptional regulation of the mouse CSF-1 gene. Molecular Reproduction and Development. 46(1). 39–45. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact